Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065286 | 0.89 | PDE4A (0.40) | PDE4APDE4BPDE4DPDE4CKLK7 | |
| SCHEMBL2065708 | 0.86 | PDE4A (0.39) | PDE4APDE4BPDE4DPDE4CCDK2 | |
| SCHEMBL2066389 | 0.79 | PDE4A (0.39) | PDE4APDE4BPDE4DPDE4CKLK7 | |
| SCHEMBL2066681 | 0.78 | PDE4A (0.40) | PDE4APDE4BPDE4DPDE4CKLK7 | |
| SCHEMBL2066602 | 0.78 | PDE10A (0.32) | GLP1R | |
| SCHEMBL2067978 | 0.76 | PDE4A (0.36) | PDE4APDE4BPDE4DPDE4CKLK7 | |
| SCHEMBL2068562 | 0.75 | PDE4B (0.35) | PDE4APDE4BPDE4DPDE4CKLK7 | |
| SCHEMBL2067969 | 0.75 | PDE4B (0.35) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL2066954 | 0.74 | PDE4A (0.40) | PDE4APDE4BPDE4DPDE4CKLK7 | |
| SCHEMBL2066599 | 0.74 | PDE4A (0.37) | PDE4APDE4BPDE4DPDE4CKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148524-B2 | Process for producing sulfonyl chloride compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-1932846-B1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-1932846-A1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SALL4, CLCN2, CLIC1 | PDE4A 4317/4885PDE4B 4162/4885PDE4D 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.